MATERNUS-KLINIKEN AG (MAK.DE) Stock Fundamental Analysis

FRA:MAK • DE0006044001

0.95 EUR
+0.01 (+1.06%)
Last: Feb 26, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

Taking everything into account, MAK scores 1 out of 10 in our fundamental rating. MAK was compared to 30 industry peers in the Health Care Providers & Services industry. MAK may be in some trouble as it scores bad on both profitability and health. MAK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MAK has reported negative net income.
  • MAK had a positive operating cash flow in the past year.
  • In the past 5 years MAK always reported negative net income.
  • In the past 5 years MAK always reported a positive cash flow from operatings.
MAK.DE Yearly Net Income VS EBIT VS OCF VS FCFMAK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -9.59%, MAK is doing worse than 90.00% of the companies in the same industry.
Industry RankSector Rank
ROA -9.59%
ROE N/A
ROIC N/A
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAK.DE Yearly ROA, ROE, ROICMAK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

1.3 Margins

  • MAK has a better Gross Margin (86.65%) than 83.33% of its industry peers.
  • MAK's Gross Margin has been stable in the last couple of years.
  • MAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
MAK.DE Yearly Profit, Operating, Gross MarginsMAK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • MAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MAK has about the same amount of shares outstanding.
  • The number of shares outstanding for MAK remains at a similar level compared to 5 years ago.
  • Compared to 1 year ago, MAK has a worse debt to assets ratio.
MAK.DE Yearly Shares OutstandingMAK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MAK.DE Yearly Total Debt VS Total AssetsMAK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • MAK has an Altman-Z score of -0.99. This is a bad value and indicates that MAK is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -0.99, MAK is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
  • MAK has a debt to FCF ratio of 19.09. This is a negative value and a sign of low solvency as MAK would need 19.09 years to pay back of all of its debts.
  • The Debt to FCF ratio of MAK (19.09) is worse than 63.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.09
Altman-Z -0.99
ROIC/WACCN/A
WACC3.92%
MAK.DE Yearly LT Debt VS Equity VS FCFMAK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • MAK has a Current Ratio of 0.22. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MAK has a worse Current ratio (0.22) than 80.00% of its industry peers.
  • MAK has a Quick Ratio of 0.22. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MAK has a worse Quick ratio (0.21) than 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.22
Quick Ratio 0.21
MAK.DE Yearly Current Assets VS Current LiabilitesMAK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.72% over the past year.
  • MAK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.43%.
  • MAK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.73% yearly.
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%3.79%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAK.DE Yearly Revenue VS EstimatesMAK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MAK.DE Yearly EPS VS EstimatesMAK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 -0.02 -0.04 -0.06

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • MAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAK.DE Price Earnings VS Forward Price EarningsMAK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MAK indicates a rather expensive valuation: MAK more expensive than 80.00% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MAK indicates a rather cheap valuation: MAK is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 2.03
EV/EBITDA 19.84
MAK.DE Per share dataMAK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MAK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MATERNUS-KLINIKEN AG

FRA:MAK (2/26/2026, 7:00:00 PM)

0.95

+0.01 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)09-30
Earnings (Next)04-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners81.7%
Ins Owner ChangeN/A
Market Cap19.92M
Revenue(TTM)114.00M
Net Income(TTM)-13.16M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF 2.03
P/OCF 2.01
P/B N/A
P/tB N/A
EV/EBITDA 19.84
EPS(TTM)-0.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.47
FCFY49.18%
OCF(TTM)0.47
OCFY49.65%
SpS5.44
BVpS-3.29
TBVpS-3.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.65%
FCFM 8.59%
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
F-Score4
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.09
Debt/EBITDA 12.53
Cap/Depr 0.79%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion 102.07%
Profit Quality N/A
Current Ratio 0.22
Quick Ratio 0.21
Altman-Z -0.99
F-Score4
WACC3.92%
ROIC/WACCN/A
Cap/Depr(3y)22.85%
Cap/Depr(5y)18.44%
Cap/Sales(3y)2.27%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%3.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y595.8%
FCF growth 3Y-3.29%
FCF growth 5Y-1.66%
OCF growth 1Y14887.9%
OCF growth 3Y-4.38%
OCF growth 5Y-1.22%

MATERNUS-KLINIKEN AG / MAK.DE FAQ

Can you provide the ChartMill fundamental rating for MATERNUS-KLINIKEN AG?

ChartMill assigns a fundamental rating of 1 / 10 to MAK.DE.


What is the valuation status of MATERNUS-KLINIKEN AG (MAK.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to MATERNUS-KLINIKEN AG (MAK.DE). This can be considered as Overvalued.


How profitable is MATERNUS-KLINIKEN AG (MAK.DE) stock?

MATERNUS-KLINIKEN AG (MAK.DE) has a profitability rating of 2 / 10.


Can you provide the financial health for MAK stock?

The financial health rating of MATERNUS-KLINIKEN AG (MAK.DE) is 0 / 10.